Development of a Peptide-Based SARS-CoV-2 Candidate Vaccine
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 20-003578
About this study
The purpose of this study is to identify SARS-CoV-2 peptides capable of being processed and presented by antigen presenting cells during viral infection, to test peptides for biologic/immunologic relevance in PBMCs from recovered COVID-19+ cases, and to perform in vivo infection studies in mice (ACE2 x HLA A2 transgenic) using individual peptide and/or peptide combinations with and without adjuvants to identify the optimal protective potential of the identified peptide/peptides against wild virus challenge.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Age: 18 and over.
- 30 days after a clinical or laboratory diagnosis of COVID-19.
- Willingness and ability to provide written informed consent.
- Generally healthy, as determined by study investigators, and not meeting any of the exclusion criteria listed below.
Exclusion Criteria:
- Individuals under 18 years of age.
- Currently pregnant.
- Immunocompromising medical conditions (diabetes mellitus, autoimmune diseases, chronic kidney disease, liver disease, HIV infection, malignancy, or other conditions deemed by the study investigators to be immunocompromising).
- Subject has current anticoagulant therapy or history of bleeding diathesis.
- Weighs ≤ 110 lbs.
- Receipt of oral prednisone or other immunosuppressive medications within 30 days prior to the study blood draw (inhaled, intranasal, or intra-articular corticosteroids are permitted).
- Transgender women/men will be excluded due to the potential impact of this status on immune response.
- Recipient of any blood/blood product transfusion within the last 30 days.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Richard Kennedy, Ph.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available